ArriVent BioPharma (AVBP) announced the appointment of Brent Rice as chief commercial officer. Rice joins ArriVent with over 25 years of U.S. and global commercial experience in the biotechnology and pharmaceutical industry. Before joining ArriVent, Brent most recently served as the senior VP and global chief commercial officer, and managing director U.S. at Autolus Therapeutics (AUTL).
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVBP:
- 3 Best Stocks to Buy Now, 9/10/2025, According to Top Analysts
- ArriVent BioPharma Buy Rating: Strong Clinical Data and Strategic Positioning Highlight Potential
- Promising Market Position and Strong Clinical Results Lead to Buy Rating for ArriVent BioPharma, Inc.
- ArriVent BioPharma Announces Promising Phase 1b Study Results
- ArriVent Biopharma presents proof-of-concept data from Phase 1b FURTHER trial